Literature DB >> 14661916

A fluorescent hPept1 transporter substrate for uptake screening.

Christopher P Landowski1, Hyo-kyung Han, Kyung-Dall Lee, Gordon L Amidon.   

Abstract

PURPOSE: To synthesize fluorescent analogues of hPept1 substrates, FITC-Val-OCH3, Lys-FITC-OH, and Lys-FITC-OCH3, and to characterize their hPept1 transporter-mediated uptake.
METHODS: FITC analogues of amino acids were synthesized using established synthetic procedures, and the extent of their [3H]Gly-Sar uptake inhibition in HeLa/hPept1 cells was determined. The uptake of Lys-FITC-OCH3 was evaluated in HeLa, HeLa/hPept1, and Caco-2 cells in the presence and absence of Gly-Sar using a fluorescence microscopy-based assay. The uptake and transport of the Lys-FITC analogues were also determined in Caco-2 cells using HPLC assays.
RESULTS: In HeLa/hPept1 cells, [3H]Gly-Sar uptake was significantly inhibited by Lys-FITC-OCH3 (74%) but not by FITC-Val-OCH3 (22%). The uptake of Lys-FITC-OCH3 (100 microM) was approximately 10-fold higher in HeLa/hPept1 cells. Also, Lys-FITC-OCH3 (100 microM) uptake in HeLa/hPept1 and Caco-2 cells was reduced by 77% and 80%, respectively, in the presence of 1 mM Gly-Sar. Dipeptides and cephalexin significantly reduced Lys-FITC-OCH3 uptake in Caco-2 cells. The apical permeability of Lys-FITC-OCH3 (1.5 x 10(6) cm/s) in Caco-2 cells was significantly lowered in the presence of Gly-Sar. Fluorescence micrographs revealed that this analogue was localized in the cytoplasm and in the nucleus.
CONCLUSIONS: The combined results indicate that Lys-FITC-OCH3 is recognized and transported by hPept1 in HeLa/hPept1 and by peptide transporters in Caco-2 cells. The results also suggest that Lys-FITC-OCH3 might be a useful fluorescent substrate for rapid assessment of peptide transporter activity in cells of interest.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14661916     DOI: 10.1023/b:pham.0000003369.64891.51

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Human pharmacokinetics and tolerance of oral ganciclovir.

Authors:  M A Jacobson; P de Miranda; D M Cederberg; T Burnette; E Cobb; H R Brodie; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

2.  Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2.

Authors:  M Sugawara; W Huang; Y J Fei; F H Leibach; V Ganapathy; M E Ganapathy
Journal:  J Pharm Sci       Date:  2000-06       Impact factor: 3.534

3.  Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects.

Authors:  D Jung; A Dorr
Journal:  J Clin Pharmacol       Date:  1999-08       Impact factor: 3.126

4.  Photosensitization of pancreatic tumour cells by delta-aminolaevulinic acid esters.

Authors:  C J Whitaker; S H Battah; M J Forsyth; C Edwards; R W Boyle; E K Matthews
Journal:  Anticancer Drug Des       Date:  2000-06

5.  Intestinal peptide transport: ex vivo uptake studies and localization of peptide carrier PEPT1.

Authors:  D A Groneberg; F Döring; P R Eynott; A Fischer; H Daniel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-09       Impact factor: 4.052

6.  5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter.

Authors:  H Han; R L de Vrueh; J K Rhie; K M Covitz; P L Smith; C P Lee; D M Oh; W Sadée; G L Amidon
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

7.  Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.

Authors:  S Weller; M R Blum; M Doucette; T Burnette; D M Cederberg; P de Miranda; M L Smiley
Journal:  Clin Pharmacol Ther       Date:  1993-12       Impact factor: 6.875

8.  H+ coupled active transport of bestatin via the dipeptide transport system in rabbit intestinal brush-border membranes.

Authors:  K Inui; Y Tomita; T Katsura; T Okano; M Takano; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1992-02       Impact factor: 4.030

Review 9.  Pharmacokinetics of acyclovir after intravenous and oral administration.

Authors:  P de Miranda; M R Blum
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

10.  Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter.

Authors:  H K Han; D M Oh; G L Amidon
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

View more
  4 in total

Review 1.  Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers.

Authors:  Marlyn Laksitorini; Vivitri D Prasasty; Paul K Kiptoo; Teruna J Siahaan
Journal:  Ther Deliv       Date:  2014-10

2.  Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.

Authors:  Xiaomei I Liu; Jeremiah D Momper; Natella Rakhmanina; John N van den Anker; Dionna J Green; Gilbert J Burckart; Brookie M Best; Mark Mirochnick; Edmund V Capparelli; André Dallmann
Journal:  J Clin Pharmacol       Date:  2019-09-06       Impact factor: 3.126

3.  Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.

Authors:  Qi Cheng; Nishank Shah; Angelika Bröer; Stephen Fairweather; Yang Jiang; Dieter Schmoll; Ben Corry; Stefan Bröer
Journal:  Br J Pharmacol       Date:  2017-02-14       Impact factor: 8.739

4.  Design of high-affinity peptide conjugates with optimized fluorescence quantum yield as markers for small peptide transporter PEPT1 (SLC15A1).

Authors:  Praveen M Bahadduri; Abhijit Ray; Akash Khandelwal; Peter W Swaan
Journal:  Bioorg Med Chem Lett       Date:  2008-03-20       Impact factor: 2.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.